BioSpace News Archive

Olympus announced a new exclusive distribution agreement with EndoClot® Plus, Inc. that extends our strategic partnership to the Europe, Middle East and Africa region.

UCLA data in the Journal of Clinical Investigation supports LR09 drug development as a metabolic immune checkpoint inhibitor for the treatment of leukemia

Kuick Research Report Highlights Emerging Role Of Checkpoint Inhibitors in Cancer Therapy With Insight on Ongoing Clinical Trials And Approved Combination Therapies

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that its psilocybin preclinical study has been published in the Journal of Psychopharmacology, a fully peer-reviewed, international science journal.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) is pleased to announce the formation of a multiple myeloma advisory board (“MM Advisory Board”).

Psilera is proud to be an invited presenter at the Biotech Showcase of 2023 in San Francisco, CA.

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 vaccines to include use in children down to 6 months of age.

ReviR Therapeutics (ReviR), a biotechnology company developing small molecule therapies targeting RNA, today announced an upcoming presentation at the 5th Annual RNA Targeted Drug Discovery conference taking place December 13-15, 2022 in Boston, MA.

The Allen Institute announced six new Next Generation Leaders, members of a unique neuroscience advisory panel made up of early-career researchers who will help advise research efforts at the Allen Institute for Brain Science, the MindScope Program, and the Allen Institute for Neural Dynamics.

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children 6 months through 5 years of age.